127 related articles for article (PubMed ID: 23164603)
1. Anti-HBV agents derived from botanical origin.
Qiu LP; Chen KP
Fitoterapia; 2013 Jan; 84():140-57. PubMed ID: 23164603
[TBL] [Abstract][Full Text] [Related]
2. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.
Qiu LP; Chen L; Chen KP
Fundam Clin Pharmacol; 2014 Aug; 28(4):364-81. PubMed ID: 24118072
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in antivirals against hepatitis B virus.
Wang YJ; Yang L; Zuo JP
Virus Res; 2016 Feb; 213():205-213. PubMed ID: 26732483
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives.
Sun D; Zhu L; Yao D; Chen L; Fu L; Ouyang L
Eur J Med Chem; 2018 Mar; 147():205-217. PubMed ID: 29438889
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
8. UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
De Nicolò A; Simiele M; Pensi D; Boglione L; Allegra S; Di Perri G; D'Avolio A
J Pharm Biomed Anal; 2015 Oct; 114():127-32. PubMed ID: 26037161
[TBL] [Abstract][Full Text] [Related]
9. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future.
Férir G; Kaptein S; Neyts J; De Clercq E
Rev Med Virol; 2008; 18(1):19-34. PubMed ID: 17966115
[TBL] [Abstract][Full Text] [Related]
10. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of chronic hepatitis B in HIV co-infected patients].
Massard J; Benhamou Y
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt 2):S20-4. PubMed ID: 18662606
[TBL] [Abstract][Full Text] [Related]
12. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
13. Therapy of chronic hepatitis B: trends and developments.
Delaney WE; Borroto-Esoda K
Curr Opin Pharmacol; 2008 Oct; 8(5):532-40. PubMed ID: 18835366
[TBL] [Abstract][Full Text] [Related]
14. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
15. Management of chronic hepatitis B virus infection: a new era of disease control.
Farrell GC; Teoh NC
Intern Med J; 2006 Feb; 36(2):100-13. PubMed ID: 16472264
[TBL] [Abstract][Full Text] [Related]
16. [Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients].
von Wagner M; Zeuzem S
Dtsch Med Wochenschr; 2009 Feb; 134(6):255-8. PubMed ID: 19180418
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir for the treatment of hepatitis B virus.
Jenh AM; Thio CL; Pham PA
Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
[TBL] [Abstract][Full Text] [Related]
18. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
19. Customizing the management of chronic hepatitis B virus infection.
Gish RG; Perrillo RP; Jacobson IM
Semin Liver Dis; 2007 Aug; 27 Suppl 1():9-17. PubMed ID: 17701845
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
